Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
- Author
- WALLENTIN, Lars1 ; YUSUF, Salim2 ; POGUE, Janice2 ; REILLY, Paul A9 ; YANG, Sean9 ; CONNOLLY, Stuart J2 ; EZEKOWITZ, Michael D3 ; ALINGS, Marco4 ; FLATHER, Marcus5 ; GRAZIA FRANZOSI, Maria6 ; PAIS, Prem7 ; DANS, Antonio8 ; EIKELBOOM, John2 ; OLDGREN, Jonas1
[1] Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
[2] Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada
[3] Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, United States
[4] Cardiovascular Research the Netherlands, Utrecht, Netherlands
[5] Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom
[6] Department of Cardiovascular Research Istituto Mario Negri, Milan, Italy
[7] St John's Medical College and Research Institute, Bangalore, India
[8] College of Medicine, University of the Philippines, Manila, Philippines
[9] Boehririger Ingelheim, Ridgefield, CT, United States
RE-LY investigators - Source
Lancet (British edition). 2010, Vol 376, Num 9745, pp 975-983, 9 p ; ref : 19 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Accident cérébrovasculaire Anticoagulant Antithrombotique Contrôle Dabigatran Efficacité traitement Essai clinique Etude comparative Fibrillation auriculaire Médecine Procès Prévention Rapport INR Surveillance Sécurité Toxicité Warfarine Antithrombine Antivitamine K Cardiopathie Dérivé de la coumarine Enzyme Hydrolases Inhibiteur enzyme Pathologie cérébrovasculaire Pathologie de l'appareil circulatoire Pathologie de l'encéphale Pathologie des vaisseaux sanguins Pathologie du système nerveux central Pathologie du système nerveux Peptidases Serine endopeptidases Thrombin Trouble de l'excitabilité Trouble du rythme cardiaque
- Keyword (en)
- Stroke Anticoagulant Antithrombotic agent Check Dabigatran Treatment efficiency Clinical trial Comparative study Atrial fibrillation Medicine Trial Prevention International normalized ratio Surveillance Safety Toxicity Warfarin Antithrombin Antivitamin K Heart disease Coumarine derivatives Enzyme Hydrolases Enzyme inhibitor Cerebrovascular disease Cardiovascular disease Cerebral disorder Vascular disease Central nervous system disease Nervous system diseases Peptidases Serine endopeptidases Thrombin Excitability disorder Arrhythmia
- Keyword (es)
- Accidente cerebrovascular Anticoagulante antitrombōtico Control Dabigatrán Eficacia tratamiento Ensayo clínico Estudio comparativo Fibrilación auricular Medicina Prevención Razón normalizada internacional Vigilancia Seguridad Toxicidad Warfarina Antitrombina Antivitamina K Cardiopatía Enzima Hydrolases Inhibidor enzima Vaso sanguíneo encéfalo patología Aparato circulatorio patología Encéfalo patología Vaso sanguíneo patología Sistema nervosio central patología Sistema nervioso patología Peptidases Serine endopeptidases Thrombin Trastorno excitabilidad Arritmia
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17C Vascular diseases and vascular malformations of the nervous system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B30 Public health. Hygiene-occupational medicine / 002B30A Public health. Hygiene / 002B30A03 Prevention and actions
- Discipline
- Generalities in medical sciences Neurology Public health. Hygiene-occupational medicine
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 23239608
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(10)61194-4 
https://dx.doi.org/10.1016/S0140-6736(10)61194-4
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)61194-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"376\";s:8:\"\u0000*\u0000issue\";s:4:\"9745\";s:8:\"\u0000*\u0000spage\";s:3:\"975\";s:8:\"\u0000*\u0000epage\";s:3:\"983\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WALLENTIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Lars\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"YUSUF, Salim\";i:1;s:13:\"POGUE, Janice\";i:2;s:14:\"REILLY, Paul A\";i:3;s:10:\"YANG, Sean\";i:4;s:18:\"CONNOLLY, Stuart J\";i:5;s:20:\"EZEKOWITZ, Michael D\";i:6;s:13:\"ALINGS, Marco\";i:7;s:15:\"FLATHER, Marcus\";i:8;s:22:\"GRAZIA FRANZOSI, Maria\";i:9;s:10:\"PAIS, Prem\";i:10;s:13:\"DANS, Antonio\";i:11;s:15:\"EIKELBOOM, John\";i:12;s:14:\"OLDGREN, Jonas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)61194-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"376\";s:8:\"\u0000*\u0000issue\";s:4:\"9745\";s:8:\"\u0000*\u0000spage\";s:3:\"975\";s:8:\"\u0000*\u0000epage\";s:3:\"983\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WALLENTIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Lars\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"YUSUF, Salim\";i:1;s:13:\"POGUE, Janice\";i:2;s:14:\"REILLY, Paul A\";i:3;s:10:\"YANG, Sean\";i:4;s:18:\"CONNOLLY, Stuart J\";i:5;s:20:\"EZEKOWITZ, Michael D\";i:6;s:13:\"ALINGS, Marco\";i:7;s:15:\"FLATHER, Marcus\";i:8;s:22:\"GRAZIA FRANZOSI, Maria\";i:9;s:10:\"PAIS, Prem\";i:10;s:13:\"DANS, Antonio\";i:11;s:15:\"EIKELBOOM, John\";i:12;s:14:\"OLDGREN, Jonas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)61194-4\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)61194-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"376\";s:8:\"\u0000*\u0000issue\";s:4:\"9745\";s:8:\"\u0000*\u0000spage\";s:3:\"975\";s:8:\"\u0000*\u0000epage\";s:3:\"983\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WALLENTIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Lars\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"YUSUF, Salim\";i:1;s:13:\"POGUE, Janice\";i:2;s:14:\"REILLY, Paul A\";i:3;s:10:\"YANG, Sean\";i:4;s:18:\"CONNOLLY, Stuart J\";i:5;s:20:\"EZEKOWITZ, Michael D\";i:6;s:13:\"ALINGS, Marco\";i:7;s:15:\"FLATHER, Marcus\";i:8;s:22:\"GRAZIA FRANZOSI, Maria\";i:9;s:10:\"PAIS, Prem\";i:10;s:13:\"DANS, Antonio\";i:11;s:15:\"EIKELBOOM, John\";i:12;s:14:\"OLDGREN, Jonas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)61194-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"376\";s:8:\"\u0000*\u0000issue\";s:4:\"9745\";s:8:\"\u0000*\u0000spage\";s:3:\"975\";s:8:\"\u0000*\u0000epage\";s:3:\"983\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WALLENTIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Lars\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"YUSUF, Salim\";i:1;s:13:\"POGUE, Janice\";i:2;s:14:\"REILLY, Paul A\";i:3;s:10:\"YANG, Sean\";i:4;s:18:\"CONNOLLY, Stuart J\";i:5;s:20:\"EZEKOWITZ, Michael D\";i:6;s:13:\"ALINGS, Marco\";i:7;s:15:\"FLATHER, Marcus\";i:8;s:22:\"GRAZIA FRANZOSI, Maria\";i:9;s:10:\"PAIS, Prem\";i:10;s:13:\"DANS, Antonio\";i:11;s:15:\"EIKELBOOM, John\";i:12;s:14:\"OLDGREN, Jonas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)61194-4\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"376\";s:8:\"\u0000*\u0000issue\";s:4:\"9745\";s:8:\"\u0000*\u0000spage\";s:3:\"975\";s:8:\"\u0000*\u0000epage\";s:3:\"983\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WALLENTIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Lars\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:12:\"YUSUF, Salim\";i:1;s:13:\"POGUE, Janice\";i:2;s:14:\"REILLY, Paul A\";i:3;s:10:\"YANG, Sean\";i:4;s:18:\"CONNOLLY, Stuart J\";i:5;s:20:\"EZEKOWITZ, Michael D\";i:6;s:13:\"ALINGS, Marco\";i:7;s:15:\"FLATHER, Marcus\";i:8;s:22:\"GRAZIA FRANZOSI, Maria\";i:9;s:10:\"PAIS, Prem\";i:10;s:13:\"DANS, Antonio\";i:11;s:15:\"EIKELBOOM, John\";i:12;s:14:\"OLDGREN, Jonas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:195:\"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
